Cell MedX Corp (CMXC) reported QQ4 2024 results that reflect a nascent operating profile with no disclosed revenue and a material net loss, underscored by acute liquidity constraints. Operating income was negative at -$116,960 and net income came in at -$124,957 for the quarter, with EPS of -0.003. Depreciation and amortization contributed a non-cash expense of $84,130, while general and administrative expenses dominated quarterly spend at $119,023, with R&D outlays of $2,062. Free cash flow was negative at -$30,259, and net cash provided by operating activities stood at -$30,256, signaling ongoing cash burn despite a modest quarterly capital outlay of $3 for capex.
The balance sheet shows a distressed liquidity position: cash and cash equivalents of $43,415 versus total current liabilities of $872,577, resulting in a current ratio of approximately 0.053. Total liabilities rest at $872,577 against total assets of $46,122, yielding negative stockholders’ equity of about -$826,455. Net debt approximates $244,051, highlighting a delicate run-way that depends on external financing or a meaningful revenue/partnering inflection. The company’s stated market position revolves around the eBalance professional and home systems for wellness and pain management, but the QQ4 2024 results indicate that financial health and near-term profitability are constraining value realization. Management commentary or transcript context is not provided in the data set, limiting clarity on near-term strategic catalysts. Investors should monitor liquidity developments, potential partnerships, or licensing arrangements that could unlock value, as well as any forward-looking guidance disclosed in forthcoming filings or calls.